A new application for therapeutic RNA is being explored by the UK start-up company Transine Therapeutics Ltd. On 2 June, Transine announced receipt of an extended £9.1 million in seed financing. The funding round was co-led by Takeda Ventures Inc and the Dementia Discovery Fund (DDF), a specialist venture capital fund supported by private industry, charities, and the UK government.
